Last Updated: 03/10/2025
Elucidation of respiratory chain inhibitor resistance mechanisms by mitochondrial genome editing in malaria parasites
Objectives
The main aim of this study is to establish mitochondrial genome editing technology for malaria parasites and to clarify the drug resistance mechanism by biochemical analysis of the mutants created.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Atovaquone is an antimalarial drug that targets the cytochrome bc1 complex of malaria parasites, and malaria parasites acquire drug resistance due to amino acid mutations in cytochrome b encoded in the mitochondrial genome. However, because mitochondrial genome editing technology for malaria parasites has not been established, it has not been possible to quantitatively examine the effects of amino acid mutations.
External reference
Date
Apr 2025 — Mar 2027
Total Project Funding
$56,648
Funding Details
Project Site
Related Resources
